Nucl Med Mol Imaging.
2018 Jun;52(3):216-223. 10.1007/s13139-017-0503-8.
Evaluating the Predictive Ability of Initial Staging F-18 FDG PET/CT for the Prognosis of Non-HodgkinMalignant Lymphoma Patients Who Underwent Stem Cell Transplantation
- Affiliations
-
- 1Department of Nuclear Medicine, Busan Paik Hospital, University of Inje College of Medicine, 75 Bokji-ro, Busanjin-gu, Busan 47392, Republic of Korea. narrowroad@inje.ac.kr
- 2Department of Nuclear Medicine, Haundae Paik Hospital, University of Inje College of Medicine, 875 Haeun-daero, Haeundae-gu, Busan 48108, Republic of Korea.
- 3Department of Internal Medicine, Busan Paik Hospital, University of Inje College of Medicine, 75 Bokji-ro, Busanjin-gu, Busan 47392, Republic of Korea.
- KMID: 2414812
- DOI: http://doi.org/10.1007/s13139-017-0503-8
Abstract
OBJECTIVES
This study aimed to determine the value of clinical prognostic factors and semiquantitative metabolic parameters from initial staging fluorine-18 fluorodeoxyglucose positron emission tomography/computed tomography (F-18 FDG PET/CT) in non-Hodgkin lymphoma (NHL) patients treated with stem cell transplantation (SCT).
METHODS
A total of 39 malignant lymphoma patients who underwent initial staging F-18 FDG PET/CT were enrolled in this study. SUVmax, MTV_wb, and TLG_wb were measured during the initial staging PET/CT. Receiver operating characteristic curve (ROC) analysis was adopted to dichotomize continuous variables. Log-rank test and Cox proportional hazard regression analysis were used to evaluate disease-free survival (DFS) rate.
RESULTS
Among the 39 patients with malignant lymphoma, 17 (43.6%) had a relapse. For several clinical factors such as age, ECOG performance score, AMC/ALC score, stages, and revised International Prognostic Index score, differences between the two dichotomized groups were statistically insignificant. In univariate analysis, DFS estimates were 71.0 ± 7.8 months and 18.0 ± 5.9 months in high-SUVmax and low-SUVmax group, respectively (P < 0.01). For MTV_wb, DFS estimates were 46.6 ± 12.4 months and 69.1 ± 8.5 months in high-MTV_wb and low-MTV_wb group, respectively (P = 0.12). For TLG_wb, DFS estimates were 65.3 ± 7.5 months and 13.7 ± 8.6 months in high-TLG_wb and low-TLG_wb group, respectively (P = 0.02). In Cox proportional hazard regression analysis, only MTV_wb showed statistical significance (HR 3.01, 95% CI 1.04−8.74, P = 0.04).
CONCLUSION
In NHL patients treated with SCT, the MTV_wb of initial staging F-18 FDG PET/CTwas an independent prognostic factor.
Keyword
- Full Text Links
-
- Actions
-
Cited
- CITED
-
- Close
- Share
-
- Similar articles
-
- Staging and response assessment of lymphoma: a brief review of the Lugano classification and the role of FDG-PET/CT
- F-18 FDG PET/CT Findings of Subcutaneous Panniculitis - Like T- Cell Lymphoma : A Case Report
- Usefulness of F-18 FDG PET/CT in Staging of Peripheral T Cell Lymphoma
- The Role of PET in Staging Non-Small Cell Lung Cancer
- The Use of PET in Esophageal Cancer
